NASDAQ · NPCE
Healthcare · Medical - Devices
$12.39
Down-$0.37 (-2.90%)
Updated Oct 9, 2026, 4:59 AM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NPCE
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
NPCE closed at $12.39 after 21 trading sessions, down 10.67% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $12.66 | $12.66 | $12.28 | $12.39 | 142.58K |
| Oct 7, 2026 | $12.58 | $13.06 | $12.51 | $12.76 | 127.18K |
| Oct 6, 2026 | $13.38 | $13.38 | $12.66 | $12.67 | 83.59K |
| Oct 5, 2026 | $12.64 | $13.26 | $12.50 | $13.22 | 149.43K |
| Oct 2, 2026 | $13.34 | $13.34 | $12.68 | $12.70 | 120.42K |
| Oct 1, 2026 | $13.81 | $13.81 | $13.05 | $13.15 | 197.4K |
| Sep 30, 2026 | $14.02 | $14.06 | $13.73 | $13.76 | 120.88K |
| Sep 29, 2026 | $14.14 | $14.45 | $13.77 | $13.94 | 100.58K |
| Sep 28, 2026 | $14.01 | $14.18 | $13.75 | $14.15 | 134.55K |
| Sep 25, 2026 | $13.95 | $14.18 | $13.75 | $14.06 | 231.41K |
| Sep 24, 2026 | $14.21 | $14.21 | $13.5937 | $13.97 | 186.06K |
| Sep 23, 2026 | $14.71 | $14.867 | $14.17 | $14.21 | 166.39K |
| Sep 22, 2026 | $14.75 | $14.9349 | $14.54 | $14.71 | 160.48K |
| Sep 21, 2026 | $14.36 | $14.66 | $14.12 | $14.54 | 71.73K |
| Sep 18, 2026 | $14.17 | $14.5599 | $14.05 | $14.28 | 235.66K |
| Sep 17, 2026 | $14.34 | $14.34 | $13.965 | $14.15 | 108.26K |
| Sep 16, 2026 | $14.28 | $14.57 | $14.04 | $14.10 | 116.14K |
| Sep 15, 2026 | $14.48 | $14.49 | $14.0506 | $14.25 | 96.84K |
| Sep 14, 2026 | $14.01 | $14.655 | $13.95 | $14.59 | 125.89K |
| Sep 11, 2026 | $14.04 | $14.13 | $13.815 | $14.04 | 107.48K |
| Sep 10, 2026 | $14.46 | $14.465 | $13.825 | $13.87 | 73.03K |
The latest Smart Investors Daily articles mentioning NPCE.
Company
Market Activity
Research & News
NPCE research
Company profile and research snapshot.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 18, 2026 | Keybanc | Overweight | — |
| Jul 29, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 23, 2026 | Mizuho | Outperform | — |
| May 15, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 27, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 18, 2026
Keybanc analyst Brett Fishbin initiates coverage on NeuroPace (NASDAQ:NPCE) with a Overweight rating and announces Price Target of $18.
Yahoo · Sep 10, 2026
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo · Sep 4, 2026
NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.
Yahoo · Sep 1, 2026
MOUNTAIN VIEW, Calif., September 01, 2026--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming 2026 Cantor Global Healthcare Conference.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NPCE.
